Redeye leaves a research update following Klaria Pharma’s Q3 2023 report. As we near the end of 2023, we argue that the company draws closer to the many potential inflection points in store for the upcoming year. While Klaria Pharma’s short-term finances are a remaining hurdle, we anticipate a rights issue around year-end. However, we do not dismiss the possibility of a non-dilutive capital injection through an upcoming milestone payment or a potential licensing agreement with its sumatriptan alginate film.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Klaria Pharma Q3 2023 - Take-off is on the horizon

© Modular Finance, source Nordic Press Releases